Guest User August 28, 2023 Corporate Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
Guest User June 5, 2023 Corporate Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing
Guest User February 23, 2023 Corporate Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
Guest User January 9, 2023 Corporate Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement
Guest User November 28, 2022 Corporate Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family
Guest User October 26, 2022 Corporate NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy “Game-Changing Breakthrough”
Guest User September 13, 2022 Corporate Innovation Pharmaceuticals’ Investment in BT BeaMedical Helping Advance New Surgical Laser Platform
Guest User June 15, 2022 Corporate Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments through a New Image Guided Laser-Based Ablation Technology
Guest User March 15, 2022 Brilacidin, Corporate Innovation Pharmaceuticals Announces Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin
Guest User March 7, 2022 Brilacidin, Corporate Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases
Guest User December 7, 2021 Corporate, Brilacidin Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022
Guest User August 26, 2020 Brilacidin, Corporate Dr. William F. DeGrado, a Discoverer of Brilacidin, Joins Innovation Pharmaceuticals as Scientific Advisor
Guest User July 22, 2020 Corporate Innovation Pharmaceuticals Grants Licensing Rights to Fox Chase Chemical Diversity Center, Inc. for Antifungal Technology
Guest User July 7, 2020 Brilacidin, Corporate In Vitro Testing of Innovation Pharmaceuticals’ Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy; Manufacturing Preparation Underway for COVID-19 Clinical Trial
Guest User December 26, 2019 Brilacidin, Corporate Innovation Pharmaceuticals: Patient Screening for Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program On Track for Early January
Guest User September 30, 2019 Corporate Innovation Pharmaceuticals Engages Locust Walk, a Global Life Sciences Transaction Firm
Guest User July 29, 2019 Corporate Innovation Pharmaceuticals Provides Corporate Update Highlighting Clinical Pipeline Progress and Business Development Activities
Guest User July 22, 2019 Brilacidin, Corporate Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis
Guest User May 29, 2019 Corporate Innovation Pharmaceuticals to Attend 2019 BIO International Convention, June 3-6
Guest User February 26, 2019 Corporate Innovation Pharmaceuticals Forms Irish Subsidiary to Facilitate International Development of Clinical Pipeline
